Ignite Creation Date:
2025-12-26 @ 11:12 AM
Ignite Modification Date:
2026-03-01 @ 5:37 PM
Study NCT ID:
NCT03634228
Status:
TERMINATED
Last Update Posted:
2023-06-15
First Post:
2018-08-09
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia
Sponsor:
M.D. Anderson Cancer Center
Organization:
Study Modules
Identification Module
Status Module
Sponsor Collaborators Module
Oversight Module
Description Module
Conditions Module
Design Module
Arms Interventions Module
Outcomes Module
Eligibility Module
Contacts Locations Module
References Module
Adverse Events Module
Baseline Characteristics Module
Participant Flow Module